MANIFESTATIONS OF GLUCAGONOMA SYNDROME.
Journal
AACE clinical case reports
ISSN: 2376-0605
Titre abrégé: AACE Clin Case Rep
Pays: United States
ID NLM: 101670593
Informations de publication
Date de publication:
Historique:
received:
05
05
2019
accepted:
21
10
2019
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
12
6
2020
Statut:
epublish
Résumé
Glucagonoma is a rare neuroendocrine tumor of the pancreas. We present the case of a young female patient who presented with the major clinical manifestations of glucagonoma syndrome. The major clinical manifestations of glucagonoma syndrome are described in a 44-year-old, female patient. Beyond glucagonoma, the patient also displayed deep venous thrombosis, depression, diabetes, and necrolytic migratory erythema. We discuss the difficulty of treatment of patients with glucagonoma due to the low prevalence of the disorder, scarcity of medical evidence, lateness of diagnosis with liver metastases in most cases, and poor response to chemotherapy with high rates of relapse after surgery. In this case, pancreatectomy and hepatic lobectomy followed by somatostatin analogue therapy was the chosen treatment strategy. The clinical findings were pancreatic and hepatic masses, proximal deep venous thrombosis, depression, diabetes, and necrolytic migratory erythema. The patient also had elevated levels of glucagon. Pancreatectomy and right hepatic lobectomy were performed and confirmed the glucagonoma. Our case adds new knowledge about glucagonoma which is important due to the low incidence of the disease and the particular characteristics of the syndrome.
Identifiants
pubmed: 32524009
doi: 10.4158/ACCR-2019-0211
pmc: PMC7279770
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e46-e49Informations de copyright
Copyright © 2020 AACE.
Déclaration de conflit d'intérêts
DISCLOSURE The authors have no multiplicity of interest to disclose.
Références
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1336-1344
pubmed: 30566620
Oncol Lett. 2015 Aug;10(2):1113-1116
pubmed: 26622635
Eur J Endocrinol. 2004 Nov;151(5):531-7
pubmed: 15538929
Biomedica. 2016 Jun 03;36(2):176-81
pubmed: 27622478
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022
pubmed: 27422767
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Onco Targets Ther. 2014 Aug 14;7:1449-53
pubmed: 25152626
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Medicine (Baltimore). 1996 Mar;75(2):53-63
pubmed: 8606627
Case Rep Surg. 2016;2016:1484089
pubmed: 26981306
Am J Dermatopathol. 2019 Mar;41(3):e29-e32
pubmed: 30124507
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
Endocr Relat Cancer. 2016 Sep;23(9):R423-36
pubmed: 27461388
Oncol Lett. 2018 Mar;15(3):2749-2755
pubmed: 29435000
Med Oncol. 2007;24(3):330-7
pubmed: 17873310